US EditionHims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce
Novo Nordisk ends legal dispute with Hims & Hers to sell branded obesity drugs on telehealth, restoring a crucial revenue source and expanding direct-to-consumer reach.
6 Articles
6 Articles
Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce
Quick Read Hims & Hers (HIMS) surged 40% in aftermarket trading after falling 77% from its peak. Novo Nordisk partnered to sell Wegovy and Ozempic through Hims. Eli Lilly has been stealing market share with Zepbound. Novo Nordisk reversed from suing Hims over compounded GLP-1 drugs to partnering on branded obesity medication distribution, ending the legal feud and restoring a critical revenue stream. Finally! You can open a SoFi Crypto accoun…
Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report - Hims & Hers Health (NYSE:HIMS), Eli Lilly (NYSE:LLY)
Novo Nordisk and Hims & Hers Health have reportedly ended their legal feud and are preparing a new partnership to sell Novo's weight-loss drugs on the telehealth platform, surprising investors and sending Hims' stock sharply higher.
Media: Novo enters into partnership with the tormentor Hims & HersNovo Nordisk has reportedly entered into a partnership with the American company Hims & Hers. This is reported by Bloomberg on the basis of an unav
Novo Nordisk A/S plans to sell its weight loss drugs on the Hims & Hers Health platform, according to sources related to the agreement, ending a very public dispute between the two companies that led to a legal battle last month.Novo and Hims plan to announce a new alliance on Monday, according to the source. Both companies had a similar agreement last year, but Novo abruptly cancelled it after Hims refused to stop marketing and selling imitatio…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
